Efectos beneficiosos de la adición de ezetimiba a dosis máximas de estatinas en el control de los lípidos séricos en pacientes con diabetes mellitus tipo 2

In clinical practice, the addition of ezetimibe achieved the cLDL target in almost 60% of the patients with T2DM and dyslipidemia in the population studied, in whom maximum-dose statin monotherapy failed to achieve the recommended goals. In addition to this effect, the increase in HDL-C and the decrease in TC and TG observed reveal the importance of the addition of ezetimibe to statins in the treatment of T2DM patients with dyslipidemia.